Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 10/20 | 0.72 |
| ▸ | PPARG | P37231 | 3/20 | 0.72 |
| ▸ | FABP2 | P12104 | 2/20 | 0.72 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.72 |
| ▸ | MAPT | P10636 | 3/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.72 |
| ▸ | HPGD | P15428 | 2/20 | 0.72 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.72 |
| ▸ | TSHR | P16473 | 2/20 | 0.72 |
| ▸ | HTR2A | P28223 | 2/20 | 0.72 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.72 |
| ▸ | MEN1 | O00255 | 2/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.72 |
| ▸ | USP2 | O75604 | 2/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31084129 | 0.94 | PPARA (0.69) | PPARAPPARGFABP2SLC22A12CYP1A2 | |
| SCHEMBL2121452 | 0.92 | PPARA (0.68) | PPARAPPARGFABP2SLC22A12CYP1A2 | |
| SCHEMBL21991231 | 0.87 | PPARA (0.62) | PPARAPPARGFABP2SLC22A12CYP1A2 | |
| SCHEMBL11684008 | 0.87 | PPARA (0.62) | PPARAPPARGFABP2SLC22A12CYP1A2 | |
| SCHEMBL823203 | 0.86 | PPARA (0.70) | PPARAPPARGFABP2SLC22A12CYP1A2 | |
| SCHEMBL4755982 | 0.86 | PPARA (0.70) | PPARAPPARGFABP2SLC22A12CYP1A2 | |
| SCHEMBL11441181 | 0.86 | ELANE (0.66) | PPARAPPARGFABP2SLC22A12CYP1A2 | |
| Fenofibric Acid SCHEMBL30777817 | 0.84 | PPARA (0.72) | PPARAPPARGFABP2SLC22A12CYP1A2 | |
| SCHEMBL13984052 | 0.84 | PPARA (0.77) | PPARAPPARGFABP2SLC22A12CYP1A2 | |
| SCHEMBL822492 | 0.84 | PPARA (0.77) | PPARAPPARGFABP2SLC22A12CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-1019016-A | — | — | None | — | — | JP | disclosed |
| US-20220409566-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-12-29 | — | — | US | disclosed |
| US-20220142961-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-05-12 | — | — | US | disclosed |
| US-11318111-B2 | CCL5 inhibitors | LAPKO INC (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210196665-A1 | CCL5 Inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-10940132-B2 | CCL5 inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200138766-A1 | CCL5 INHIBITORS | LAPKO INC. DBA AFECTA PHARMACEUTICALS | 2020-05-07 | — | — | US | disclosed |
| US-20110136767-A1 | PROCESSES FOR PREPARING PIPERAZINIUM SALTS OF KMUP AND USE THEREOF | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2011-06-09 | — | — | US | disclosed |
| WO-2010086700-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF CHOLINE SALT OF FENOFIBRIC ACID AND ITS NOVEL POLYMORPH | ALEMBIC LIMITED (IN) | 2010-08-05 | — | — | WO | disclosed |
| WO-2008157537-A2 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS, INC (US) | 2008-12-24 | — | — | WO | disclosed |
| JP-S6419016-A | LIPID CONTROL COMPOSITION | WARNER LAMBERT CO | 1989-01-23 | — | — | JP | disclosed |
| JP-S06419016-A | — | — | 0001-01-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142961-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | PPARA 806/4885PPARG 1583/4885FABP2 586/4885 |
| US-20200138766-A1 | CCL5 INHIBITORS | CCL5, CCL11, CCR5 | PPARA 806/4885PPARG 1583/4885FABP2 586/4885 |
| US-20110136767-A1 | PROCESSES FOR PREPARING PIPERAZINIUM SALTS OF KMUP AND USE THEREOF | U2SURP, RRP15, KYNU | PPARA 2092/4885PPARG 1727/4885FABP2 4781/4885 |
| US-20210196665-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | PPARA 806/4885PPARG 1583/4885FABP2 586/4885 |
| US-10940132-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | PPARA 806/4885PPARG 1583/4885FABP2 586/4885 |
| US-11318111-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | PPARA 806/4885PPARG 1583/4885FABP2 586/4885 |
| US-20220409566-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | PPARA 806/4885PPARG 1583/4885FABP2 586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.